Reduced FHIT Expression Is Associated with Mismatch Repair Deficient and High CpG Island Methylator Phenotype Colorectal Cancer

Journal of Histochemistry and Cytochemistry

Volumn 61, Issue 9, 2013, Pages 627-638

  Al Temaimi, Rabeah Abbas ^a   Jacob, Sindhu ^a   Al Ali, Waleed ^a   Thomas, Diana Ann ^a   Al Mulla, Fahd ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

aCGH; colorectal cancer; CpG island methylator phenotype; fragile histidine triad gene; microsatellite instability

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; MISMATCH REPAIR PROTEIN PMS2; ACID ANHYDRIDE HYDROLASE; TUMOR PROTEIN;

ARTICLE; CANCER SURVIVAL; CHROMOSOME 3P; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; CPG ISLAND; DISEASE FREE SURVIVAL; DNA METHYLATION; EXON; FEMALE; FOLLOW UP; GENE DELETION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHYLATION; MISMATCH REPAIR; MULTIPLE SCLEROSIS; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; ACGH; COHORT ANALYSIS; COLON; COLORECTAL TUMOR; CPG ISLAND METHYLATOR PHENOTYPE; DOWN REGULATION; FRAGILE HISTIDINE TRIAD GENE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MICROSATELLITE INSTABILITY; PATHOLOGY; RECTUM;

ACGH; COLORECTAL CANCER; CPG ISLAND METHYLATOR PHENOTYPE; FRAGILE HISTIDINE TRIAD GENE; MICROSATELLITE INSTABILITY;

ACID ANHYDRIDE HYDROLASES; COHORT STUDIES; COLON; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DNA MISMATCH REPAIR; DOWN-REGULATION; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICROSATELLITE INSTABILITY; NEOPLASM PROTEINS; RECTUM;

EID: 84886792305     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/0022155413497367     Document Type: Article

References (52)

1. Al-Mulla F.Microarray-based CGH and copy number analysis of FFPE samples.Methods Mol Biol. 2011;724:131-145.
2. Al-Mulla F,Hagan S,Behbehani AI,Bitar MS,George SS,Going JJ,Garcia JJ,Scott L,Fyfe N,Murray GI, et al.Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients.J Clin Oncol. 2006;24 (36): 5672-5679.
3. Andachi H,Yashima K,Koda M,Kawaguchi K,Kitamura A,Hosoda A,Kishimoto Y,Shiota G,Ito H,Makino M, et al.Reduced Fhit expression is associated with mismatch repair deficiency in human advanced colorectal carcinoma.Br J Cancer. 2002;87 (4): 441-445.
4. Azzoni C,Bottarelli L,Campanini N,Di Cola G,Bader G,Mazzeo A,Salvemini C,Morari S,Di Mauro D,Donadei E, et al.Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis. Int J Colorectal Dis. 2007;22 (2): 115-126.
5. Barault L,Charon-Barra C,Jooste V,de la,Vega MF,Martin L,Roignot P,Rat P,Bouvier AM,Laurent-Puig P,Faivre J, et al.Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 2008;68 (20): 8541-8546.
6. Barnes LD,Garrison PN,Siprashvili Z,Guranowski A,Robinson AK,Ingram SW,Croce CM,Ohta M,Huebner K.Fhit, a putative tumor suppressor in humans, is a dinucleoside 5',5"'-P1,P3-triphosphate hydrolase.Biochemistry. 1996;35 (36): 11529-11535.
7. Beroukhim R,Getz G,Nghiemphu L,Barretina J,Hsueh T,Linhart D,Vivanco I,Lee JC,Huang JH,Alexander S, et al.Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007;104 (50): 20007-20012.
8. Boland CR,Goel A.Clearing the air on smoking and colorectal cancer.J Natl Cancer Inst. 2010;102 (14): 996-997.
9. Bosso M,Al-Mulla F.Whole genome amplification of DNA extracted from FFPE tissues.Methods Mol Biol. 2011;724:161-180.
10. Cao J,Chen XP,Li WL,Xia J,Du H,Tang WB,Wang H,Chen XW,Xiao HQ,Li YY.Decreased fragile histidine triad expression in colorectal cancer and its association with apoptosis inhibition.World J Gastroenterol. 2007;13 (7): 1018-1026.
11. Chen YJ,Chen PH,Lee MD,Chang JG.Aberrant FHIT transcripts in cancerous and corresponding non-cancerous lesions of the digestive tract.Int J Cancer. 1997;72 (6): 955-958.
12. Dahlin AM,Palmqvist R,Henriksson ML,Jacobsson M,Eklof V,Rutegard J,Oberg A,Van Guelpen BR.The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.Clin Cancer Res. 2010;16 (6): 1845-1855.
13. Dallol A,Al-Ali W,Al-Shaibani A,Al-Mulla F.Analysis of DNA methylation in FFPE tissues using the MethyLight technology.Methods Mol Biol. 2011;724:191-204.
14. Debatisse M,El Achkar E,Dutrillaux B.Common fragile sites nested at the interfaces of early and late-replicating chromosome bands: cis acting components of the G2/M checkpoint? Cell Cycle. 2006;5 (6): 578-581.
15. Dong SM,Lee EJ,Jeon ES,Park CK,Kim KM.Progressive methylation during the serrated neoplasia pathway of the colorectum.Mod Pathol. 2005;18 (2): 170-178.
16. Durkin SG,Ragland RL,Arlt MF,Mulle JG,Warren ST,Glover TW.Replication stress induces tumor-like microdeletions in FHIT/FRA3B.Proc Natl Acad Sci U S A. 2008;105 (1): 246-251.
17. Elnatan J,Murphy D,Goh HS,Smith DR.HIT family genes: FHIT but not PKCI-1/HINT produces altered transcripts in colorectal cancer. Br J Cancer. 1999;81 (5): 874-880.
18. Esteller M,Levine R,Baylin SB,Ellenson LH,Herman JG.MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas.Oncogene. 1998;17 (18): 2413-2417.
19. Ferlay J,Shin HR,Bray F,Forman D,Mathers C,Parkin DM.Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.Int J Cancer. 2010;127 (12): 2893-2917.
20. Gorgoulis VG,Vassiliou LV,Karakaidos P,Zacharatos P,Kotsinas A,Liloglou T,Venere M,Ditullio RA,Kastrinakis NG,Levy B, et al.Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.Nature. 2005;434 (7035): 907-913.
21. Hadaczek P,Debniak T,Kurzawski G,Jakubowska A,Huzarski T,Huebner K,Lubinski J.Fhit protein expression in hereditary and sporadic colorectal cancers.Pol J Pathol. 2001;52 (3): 125-132.
22. Hao XP,Willis JE,Pretlow TG,Rao JS,MacLennan GT,Talbot IC,Pretlow TP.Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions.Cancer Res. 2000;60 (1): 18-21.
23. Hawkins N,Norrie M,Cheong K,Mokany E,Ku SL,Meagher A,O'Connor T,Ward R.CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability.Gastroenterology. 2002;122 (5): 1376-1387.
24. Ionov Y,Peinado MA,Malkhosyan S,Shibata D,Perucho M.Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis.Nature. 1993;363 (6429): 558-561.
25. Ishii H,Dumon KR,Vecchione A,Fong LY,Baffa R,Huebner K,Croce CM.Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies. JAMA. 2001;286 (19): 2441-2449.
26. Jass JR.Classification of colorectal cancer based on correlation of clinical, morphological and molecular features.Histopathology. 2007;50 (1): 113-130.
27. Kang GH.Four molecular subtypes of colorectal cancer and their precursor lesions.Arch Pathol Lab Med. 2011;135 (6): 698-703.
28. Kim JH,Shin SH,Kwon HJ,Cho NY,Kang GH.Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers.Virchows Arch. 2009;455 (6): 485-494.
29. Kitamura A,Yashima K,Okamoto E,Andachi H,Hosoda A,Kishimoto Y,Shiota G,Ito H,Kaibara N,Kawasaki H.Reduced Fhit expression occurs in the early stage of esophageal tumorigenesis: no correlation with p53 expression and apoptosis. Oncology. 2001;61 (3): 205-211.
30. Lee S,Cho NY,Yoo EJ,Kim JH,Kang GH.CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. Arch Pathol Lab Med. 2008;132 (10): 1657-1665.
31. Lefevre JH,Colas C,Coulet F,Bonilla C,Mourra N,Flejou JF,Tiret E,Bodmer W,Soubrier F,Parc Y.MYH biallelic mutation can inactivate the two genetic pathways of colorectal cancer by APC or MLH1 transversions.Fam Cancer. 2010;9 (4): 589-594.
32. Lengauer C,Kinzler KW,Vogelstein B.Genetic instabilities in human cancers.Nature. 1998;396 (6712): 643-649.
33. Leopoldo S,Lorena B,Cinzia A,Gabriella DC,Angela Luciana B,Renato C,Antonio M,Carlo S,Cristina P,Stefano C, et al.Two subtypes of mucinous adenocarcinoma of the colorectum: clinicopathological and genetic features. Ann Surg Oncol. 2008;15 (5): 1429-1439.
34. Mimori K,Inoue H,Shiraishi T,Matsuyama A,Mafune K,Tanaka Y,Mori M.Microsatellite instability is often observed in esophageal carcinoma patients with allelic loss in the FHIT/FRA3B locus.Oncology. 2003;64 (3): 275-279.
35. Mimori K,Ishii H,Nagahara H,Sudo T,Yamashita K,Inoue H,Barnard GF,Mori M.FHIT is up-regulated by inflammatory stimuli and inhibits prostaglandin E2-mediated cancer progression.Cancer Res. 2006;66 (5): 2683-2690.
36. Monticone M,Daga A,Candiani S,Romeo F,Mirisola V,Viaggi S,Melloni I,Pedemonte S,Zona G,Giaretti W, et al.Identification of a novel set of genes reflecting different in vivo invasive patterns of human GBM cells.BMC Cancer. 2012;12:358.
37. Mori M,Mimori K,Masuda T,Yoshinaga K,Yamashita K,Matsuyama A,Inoue H.Absence of Msh2 protein expression is associated with alteration in the FHIT locus and Fhit protein expression in colorectal carcinoma.Cancer Res. 2001;61 (20): 7379-7382.
38. Ogino S,Kawasaki T,Brahmandam M,Cantor M,Kirkner GJ,Spiegelman D,Makrigiorgos GM,Weisenberger DJ,Laird PW,Loda M, et al.Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis.J Mol Diagn. 2006;8 (2): 209-217.
39. Ogino S,Kawasaki T,Kirkner GJ,Kraft P,Loda M,Fuchs CS.Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample.J Mol Diagn. 2007;9 (3): 305-314.
40. Ohta M,Inoue H,Cotticelli MG,Kastury K,Baffa R,Palazzo J,Siprashvili Z,Mori M,McCue P,Druck T, et al.The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers.Cell. 1996;84 (4): 587-597.
41. Pichiorri F,Ishii H,Okumura H,Trapasso F,Wang Y,Huebner K.Molecular parameters of genome instability: roles of fragile genes at common fragile sites. J Cell Biochem. 2008;104 (5): 1525-1533.
42. Pichiorri F,Palumbo T,Suh SS,Okamura H,Trapasso F,Ishii H,Huebner K,Croce CM.Fhit tumor suppressor: guardian of the preneoplastic genome. Future Oncol. 2008;4 (6): 815-824.
43. Roa SJ,Garcia MP,Melo AA,Tapia EO,Villaseca HM,Araya OJ,Guzman GP.Gene methylation patterns in digestive tumors [in Spanish].Rev Med Chil. 2008;136 (4): 451-458.
44. Ruiz-Herrera A,Castresana J,Robinson TJ.Is mammalian chromosomal evolution driven by regions of genome fragility?.Genome Biol. 2006;7 (12): R115.
45. Sanchez JA,Krumroy L,Plummer S,Aung P,Merkulova A,Skacel M,DeJulius KL,Manilich E,Church JM,Casey G, et al.Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer.Br J Surg. 2009;96 (10): 1196-1204.
46. Sarli L,Bottarelli L,Azzoni C,Campanini N,Di Cola G,Bader G,Iusco D,Salvemini C,Caruso G,Donadei E, et al.Abnormal Fhit protein expression and high frequency of microsatellite instability in sporadic colorectal cancer.Eur J Cancer. 2004;40 (10): 1581-1588.
47. Simons CC,Hughes LA,Smits KM,Khalid-de Bakker CA,de Bruine AP,Carvalho B,Meijer GA,Schouten LJ,van den Brandt PA,Weijenberg MP, et al.A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: implications for prognosis.Ann Oncol. 2013.
48. Thiagalingam S,Lisitsyn NA,Hamaguchi M,Wigler MH,Willson JK,Markowitz SD,Leach FS,Kinzler KW,Vogelstein B.Evaluation of the FHIT gene in colorectal cancers.Cancer Res. 1996;56 (13): 2936-2939.
49. Virgilio L,Shuster M,Gollin SM,Veronese ML,Ohta M,Huebner K,Croce CM.FHIT gene alterations in head and neck squamous cell carcinomas.Proc Natl Acad Sci U S A. 1996;93 (18): 9770-9775.
50. Wali A.FHIT: doubts are clear now. ScientificWorldJournal. 2010;10:1142-1151.
51. Wierzbicki PM,Adrych K,Kartanowicz D,Dobrowolski S,Stanislawowski M,Chybicki J,Godlewski J,Korybalski B,Smoczynski M,Kmiec Z.Fragile histidine triad (FHIT) gene is overexpressed in colorectal cancer.J Physiol Pharmacol. 2009;60:63-70.
52. Yasugi A,Yashima K,Hara A,Koda M,Kawaguchi K,Harada K,Andachi H,Murawaki Y.Fhit, Mlh1, P53 and phenotypic expression in the early stage of colorectal neoplasms.Oncol Rep. 2008;19 (1): 41-47.